Effect of @entity2847 on lipid plasma levels in XXXX .

@entity2847 @entity1674 @entity3216 @entity35 @entity165
Results show that @entity2847 induced marked alterations in plasma levels of @entity165 and lipids in response to acute and chronic administrations in @entity35 . Two hours after an I.P. dose of 10 mg/kg, @entity2847 caused significant reductions in plasma levels of total high density lipoprotein (HDL) and high density lipoprotein @entity165 (HDL @entity165 ). At a dose of 20 mg/kg, @entity2847 induced significant elevations in plasma levels of total @entity165 , total HDL, HDL @entity165 , total low density lipoproteins (LDL), and low density lipoprotein @entity165 (LDL @entity165 ). Injected at a dose of 4 or 10 mg/kg daily for 14 consecutive days, @entity2847 caused significant increases in plasma levels of total @entity165 , LDL @entity165 and total LDL whereas the levels of HDL @entity165 , total HDL @entity1674 (TG) were reduced. At a dose of 20 mg/kg all parameters were significantly increased. Marked hyperglycaemia was noticed in response to doses of 10, 15 and 20 mg/kg injected daily for 14 consecutive days or 2 hrs after a single administration of 15 mg/kg. Plasma insulin activity was reduced 2 hours after injection of @entity2847 at a dose of 15 mg/kg Likewise, a significant reduction in plasma insulin activity was observed in response to daily I.P. injections of @entity2847 at a dose of 15 mg/kg. Hyperglycaemic and hypoinsulinaemic effects of @entity2847 (acute and chronic) were markedly decreased when @entity3216 , a dopaminergic D2 antagonist, was injected at an I.P. dose of 10 mg/kg before @entity2847 . Plasma ACTH activity was significantly increased in response to @entity2847 (15 mg/kg I.P.) in acute and chronic experiments. This effect was markedly diminished when @entity3216 was injected prior to @entity2847 . In conclusion, @entity2847 induced marked elevations in plasma levels of total @entity165 and lipids which are likely to be related to hyperglycaemic and hypoinsulinaemic effects.
